Causaly plans to use the new funding to extend its product lead and expand its commercial relationships. The company’s AI platform is used by 12 of the top 20 pharmaceutical companies, according to a July 13 news release.
The latest funding round brings Causaly’s total raised to $93 million.
“Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust,” Causaly CEO and co-founder Yiannis Kiachopoulos said in the release. “Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.